ideaya biosciences logo

IDEAYA Biosciences

IDEAYA is an oncology-focused biotech company developing breakthrough synthetic lethality medicines, targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.

IDEAYA Biosciences was founded by Yujiro S. Hata, who earlier served as Chief Operating Officer at Flexus Biosciences (acquired by Bristol-Myers Squibb in 2015).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.ideayabio.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
7000 Shoreline Court, Suite 350,CA 94080
South San Francisco
United States
Email
Contact Number
+1 650-443-6209

In Mar 2018, IDEAYA Biosciences entered into a partnership agreement with Cancer Research UKs (CRUK) Commercial Partnerships Team and the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

IDEAYA, IO portfolio is designed to overcome the genetic and environmental factors in the tumor microenvironment that drive cancer cell evasion from both innate and adaptive immune cells, by inhibiting metabolite-driven suppression of lymphoid and myeloid cells via the Aryl Hydrocarbon Receptor.

In March 2018, IDEAYA raised $94 Mn in Series B financing. New investors, including BVF Partners L.P., Perceptive Advisors LLC, Nextech Invest Ltd., GV (formerly Google Ventures), Roche Venture Fund, 6 Dimensions Capital, Boxer Capital of the Tavistock Group, and Driehaus Capital Management, LLC, joined existing investors, including 5AM Ventures, Canaan Partners, Celgene Corporation, WuXi Healthcare Ventures, and Alexandria Venture Investments, in the financing.

In May 2016, IDEAYA raised $46 Mn in Series A round from 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research and Alexandria Real Estate.